Lupus & antiphospholipid syndrome
The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines
Authors' conclusion
This study supports the revised hemodynamic definition of SLE-PAH in the 2022 ESC/ERS guideline.
Study context
- Population
- SLE-PAH patients at Peking Union Medical College Hospital (PUMCH), 2011 to 2023
- Participants
- 236 patients
- Exposure
- Mild SLE-PAH and unclassified SLE-PH vs conventional SLE-PAH
- Mild SLE-PAHn = 22
- Unclassified SLE-PAHn = 14
- Outcome
- Prognosis (progression-free time)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Progression-free time
- Mild SLE-PAH had significantly longer progression-free time than conventional SLE-PAH
Observational data: associations, not effects.
Further findings
Prognosis in mild SLE-PAH without pulmonary arterial hypertension (PAH)-specific therapy (subgroup)
- 4 mild SLE-PAH patients did not receive PAH-specific therapy and had a similar prognosis as patients not receiving specific therapy
Original publication
The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines. Arthritis Res Ther. Published 27 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →